Skip to main content
. 2016 Oct 19;16:585. doi: 10.1186/s12879-016-1929-9

Table 1.

Risk factors for severe HFMD

Relevant factors Mild group
n = 88 (%)
Severe group
n = 128 (%)
P
Gender 0.817
 Male 55 (62.5) 78 (60.9)
 Female 33 (37.5) 50 (39.1)
Age (years) 0.557
  ≤ 3 65 (73.9) 99 (77.3)
 3–6 23 (26.1) 29 (22.7)
Fever 81 (92.0) 128 (100.0) 0.001**
 Temperature (°C) 0.000***
  37.3 to ≤38 8 (9.1) 0 (0)
  38–39 38 (43.2) 21 (16.4)
  39–40 42 (47.7) 107 (83.6)
Duration of fever (day)
  ≤ 3 65 (73.9) 39 (30.5) 0.000***
  > 3 23 (26.1) 89 (69.5)
Hypersomnia 2 (2.3) 118 (92.2) 0.000***
Hyperarousal 38 (43.2) 121 (94.5) 0.000***
Limb shaking 5 (5.7) 98 (76.6) 0.000***
Convulsion 2 (2.3) 33 (25.8) 0.000***
Vomiting 16 (18.2) 87 (68.0) 0.000***
Dyspnoea 0 (0) 71 (55.5) -
Pathologic reflexes 0 (0) 128 (100.0) -
Consciousness disorder 0 (0) 75 (58.6) -
Increased blood pressure 0 (0) 65 (50.8) -
Circulatory disturbance 0 (0) 75 (58.6) -
Laboratory examination
 Peripheral WBC count > 15 × 109/L 12 (13.6) 56 (43.8) 0.000***
 Fasting blood glucose level > 8.3 mmol/L 1 (1.1) 62 (48.4) 0.000***
 EV71-positivity 11 (12.5) 75 (58.6) 0.000***
 NT-proBNP (log10 pg/mL) 2.18 ± 0.35 3.07 ± 0.75 0.000***
 NT-proBNP >125 pg/mL 49 (55.7) 120 (93.8) 0.000***
 Increased CK 3 (3.4) 31 (24.2) 0.000***
 Increased CK-MB 36 (40.9) 58 (45.3) 0.521
 Increased LDH 2 (2.3) 18 (14.1 %) 0.001**
 Increased PCT 22 (25.0) 71 (55.5 %) 0.000***
 Deatha 0 (0) 45 (35.2 %) -
Treatment Symptomatic treatment Symptomatic treatment, glucocorticoid, IVIG, complication therapy -

HFMD hand, foot, and mouth disease, EV71 enterovirus 71, WBC White blood cell, NT-proBNP N-terminal of the prohormone brain natriuretic peptide, CK Creatine kinase isoenzyme, CK-MB Creatine kinase isoenzymeMB, LDH Lactate dehydrogenase, PCT procalcitonin, IVIG Intravenous immunoglobulins

aCauses of death were acute pulmonary edema, brainstem encephalitis and circulatory failure

*P <0.05, **P <0.01,***P <0.001